Vaxcyte (PCVX) Accumulated Depreciation (2019 - 2023)
Vaxcyte (PCVX) posted quarterly Accumulated Depreciation of $9.3 million for Q4 2023, up 51.58% year-over-year from $6.1 million in Q4 2022, and up 10.59% quarter-over-quarter from $8.4 million in Q3 2023.
Vaxcyte (PCVX) Accumulated Depreciation (2019 - 2023) Analysis & Trends
Vaxcyte (PCVX) has reported Accumulated Depreciation for 5 consecutive years, with $9.3 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Accumulated Depreciation rose 51.58% year-over-year to $9.3 million; the TTM figure through Dec 2023 stood at $9.3 million (up 51.58% YoY), while the FY2023 annual figure was $9.3 million, up 51.58% from the prior year.
- Accumulated Depreciation climbed to $9.3 million in Q4 2023 per PCVX's latest filing, from $8.4 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $9.3 million in Q4 2023 and bottomed at $3.0 million in Q4 2019.
- Historically, Accumulated Depreciation has averaged $5.3 million across 5 years, with a median of $4.8 million in 2021.
- Annual changes were most pronounced in 2021 — Accumulated Depreciation slipped 13.4% — and 2022, when it soared 72.41%.
- Vaxcyte's Accumulated Depreciation stood at $3.0 million in 2019, then surged by 37.39% to $4.1 million in 2020, then slipped by 13.4% to $3.5 million in 2021, then soared by 72.41% to $6.1 million in 2022, then soared by 51.58% to $9.3 million in 2023.
- Business Quant data shows PCVX's Accumulated Depreciation at $9.3 million in Q4 2023, $8.4 million in Q3 2023, and $7.6 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 9.27 Mn |
| Sep 30, 2023 | 8.38 Mn |
| Jun 30, 2023 | 7.58 Mn |
| Mar 31, 2023 | 6.83 Mn |
| Dec 31, 2022 | 6.12 Mn |
| Sep 30, 2022 | 5.42 Mn |
| Jun 30, 2022 | 4.73 Mn |
| Mar 31, 2022 | 4.12 Mn |
| Dec 31, 2021 | 3.55 Mn |
| Sep 30, 2021 | 5.42 Mn |
| Jun 30, 2021 | 4.93 Mn |
| Mar 31, 2021 | 4.44 Mn |
| Dec 31, 2020 | 4.10 Mn |
| Sep 30, 2020 | 3.83 Mn |
| Jun 30, 2020 | 3.50 Mn |
| Dec 31, 2019 | 2.98 Mn |